This study aims to
engineer a new type of ultrahigh quantum yield
carbon dots (CDs) from methotrexate (MTX-CDs) with self-targeting,
imaging, and therapeutic effects on MDA-MB 231 breast cancer cells.
CDs were synthesized via a straightforward thermal method using a
methotrexate (MTX) drug source. The physicochemical characteristics
of the prepared MTX-CDs were studied using Fourier transform infrared
(FT-IR) spectroscopy, transmission electron microscopy (TEM), dynamic
light scattering (DLS), X-ray powder diffraction (XRD), and X-ray
photoelectron spectroscopy (XPS). TEM and DLS revealed which MTX-CDs
have homogeneous spherical morphology with a smaller average size
of 5.4 ± 2.2 nm, polydispersity index (PDI) of 0.533, and positive
surface charge of around +3.93 mV. Results of FT-IR spectroscopy and
high-resolution XPS indicated the presence of residues of MTX on CDs.
Therefore, the synthesized MTX-CDs could be targeted and be taken
up by FR-positive cell lines without the aid of additional targeting
molecules. In vitro epifluorescence images demonstrated high-contrast
cytoplasm biodistribution of MTX-CDs after 2 h of treatment. A much
stronger fluorescent signal was detected in MDA-MB 231 compared to
MCF 7, indicating their ability to precisely target FR. The highest
cytotoxic and apoptotic effects were observed in MTX-CDs compared
to free MTX obtained by the MTT assay, cell cycle arrest, and annexin
V-FITC apoptosis techniques. Results revealed that the novel engineered
MTX-CDs were capable of inducing apoptosis (70.2% apoptosis) at a
lower concentration (3.2 μM) compared to free MTX, which was
proved by annexin V and cell cycle. This work highlights the potential
application of CDs for constructing an intelligent nanomedicine with
integration of diagnostic, targeting, and therapeutic functions.